Treatment
Decitabine clinical trials
We’re tracking 74 recruiting studies that include Decitabine, each written for real people, not researchers, below.
Recruiting studies
- NCT06129734RecruitingPhase 1/Phase 2
Decitabine and venetoclax after stem cell transplant to prevent relapse
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
Cleveland, OhioAges 18 years+ - NCT06393985RecruitingPhase 2
Maintenance therapy after stem cell transplant for B-ALL
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
Suzhou, JiangsuAges 18–65 - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT06712121RecruitingPhase 2
Venetoclax plus decitabine for relapsed or refractory T-ALL
This trial tests the combination of two drugs, venetoclax and decitabine, for people whose T-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatment. The goal is to see if this combo can help when other treatments haven't worked.
Seongnam-siAges 19–80 - NCT06827899RecruitingPhase 2
New combination therapy for older adults with untreated leukemia
This trial tests a three-drug combination (venetoclax, chidamide, and azacitidine) followed by another combination (decitabine plus MAG) for older adults with untreated acute myeloid leukemia (AML) who cannot have standard chemotherapy. It aims to offer a gentler but effective treatment option.
Xiamen, FujianAges 60 years+ - NCT06923488RecruitingPhase 1/Phase 2
Leflunomide and decitabine for returning MDS
This trial tests a new combination of two drugs—leflunomide and decitabine—for people with MDS that has come back or hasn't responded to treatment. The goal is to see if this combination can help control the disease.
Morgantown, West VirginiaAges 18 years+ - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+ - NCT07348575Enrolling by invitationPhase 3
Decitabine plus R-CHOP for EBV-positive DLBCL
This trial tests whether adding a drug called decitabine to the standard chemo-immunotherapy R-CHOP can help people with a specific type of lymphoma (DLBCL that is positive for EBV) who have not been treated before. The goal is to see if the combination works better than R-CHOP alone.
Nanchang, JiangxiAges 18–75 - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Brighton, MichiganAges 60 years+ - NCT07163793RecruitingPhase 2
Shorter venetoclax after AML remission
This trial is testing if a shorter course of venetoclax can still work well after you've already achieved remission with standard venetoclax-based treatment for AML. The goal is to reduce side effects while keeping the cancer under control.
New Hyde Park, New YorkAges 18 years+ - NCT05841771RecruitingPhase 2
Decitabine or azacitidine plus venetoclax after transplant
This trial tests two cancer medicines—decitabine or azacitidine (also called “hypomethylating agents”) plus venetoclax—given after an allogeneic stem cell transplant to help prevent relapse in people with high-risk AML or MDS. If you have measurable remaining leukemia cells after transplant, this study may be especially relevant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06701357RecruitingPhase 2
New drug combo for untreated aggressive lymphoma
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07507760RecruitingPhase 2
Oral decitabine plus ivosidenib for older AML patients
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
AlbaceteAges 18 years+ - NCT06499025Enrolling by invitationEarly Phase 1
T-cell therapy for a type of AML with the AML1-ETO gene
This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT06972641RecruitingPhase 2/Phase 3
Gene-based maintenance therapy after stem cell transplant
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 14–75 - NCT06930651RecruitingPhase 1/Phase 2
Engineered NK cell therapy for relapsed blood cancers
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
Houston, TexasAges 18–80 - NCT06383572RecruitingPhase 1/Phase 2
Modified immune cells for blood cancers after chemo
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Houston, TexasAges 18–80 - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Tucson, ArizonaAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Birmingham, AlabamaAges 18 years+ - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for certain relapsed blood cancers
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
Mankato, MinnesotaAges 18 years+ - NCT03494296Recruiting
Low-dose decitabine plus COP for relapsed lymphoma
This trial studies whether a low-dose chemotherapy medicine (decitabine) combined with a COP chemotherapy regimen can help adults whose diffuse large B-cell lymphoma (DLBCL) has come back or did not respond to treatment. It may be an option if you have measurable disease and can meet key safety and health requirements.
Harbin, HeilongjiangAges 18 years+
Common questions
- Are there clinical trials studying Decitabine?
- Yes. Clin2 currently lists 74 recruiting studies that include Decitabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Decitabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Decitabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Decitabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.